From apocalyptic dystopia to banal reality: A new materialist account of power-seeking, AI and chatbots
Thesis Eleven · 17.06.2026
DOI: 10.1177/07255136261459467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thesis Eleven, online erschienen am 17.06.2026. Verfasst von Sam Cadman und 1 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In this article we arrest the concept of ‘power-seeking’ away from apocalyptic discourses about AI's future risks to humanity. Following Latour, we suggest that while non-human actors may ‘authorize, allow, afford, encourage…[etc.]’, they can also seek power . We explain how power-seeking as a potential non-human ‘program of action’– specifically, the pursuit of increasing abilities, or authority or control over other actors – facilitates analysis of networks that enable or curb the development of technologies founded on future imaginaries. To illustrate the potential utility of power-seeking as an agency of non-human actors in the new materialist theoretical repertoire, we apply it to AI large language models, focusing on the banal reality of today's chatbots. Overall, we advance ‘power-seeking’ as a conceptual tool to analyse human–non-human dynamics, power and agency, and how associations produce outcomes that are more or less harmful or beneficial to collectives.
Zitieren
APA
Cadman, S., & Tanner, C. (2026). From apocalyptic dystopia to banal reality: A new materialist account of power-seeking, AI and chatbots. Thesis Eleven. https://doi.org/10.1177/07255136261459467
Vancouver
Cadman S, Tanner C. From apocalyptic dystopia to banal reality: A new materialist account of power-seeking, AI and chatbots. Thesis Eleven. 2026. doi:10.1177/07255136261459467
BibTeX
@article{Cadman2026,
author = {Cadman, Sam and Tanner, Claire},
title = {From apocalyptic dystopia to banal reality: A new materialist account of power-seeking, AI and chatbots},
journal = {Thesis Eleven},
year = {2026},
doi = {10.1177/07255136261459467}
}
EUVIMED